Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 7,05€(+119,63%). Der Median liegt bei 7,05€(+119,63%).
Kaufen | 3 |
Halten | 3 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party payers.» Mehr auf globenewswire.com
Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Vivian Alhorn - BTIG Joanne Lee - Maxim Group Operator Good day, and welcome to the Bionano First Quarter 2025 Earnings Conference Call. Today's conference is being recorded.» Mehr auf seekingalpha.com
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 5,97 Mio | 26,54% |
Bruttoeinkommen | 3,15 Mio | 20,25% |
Nettoeinkommen | −2,87 Mio | 90,15% |
EBITDA | −7,82 Mio | 70,12% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 10,92 Mio€ |
Anzahl Aktien | 3,36 Mio |
52 Wochen-Hoch/Tief | 53,93€ - 2,36€ |
Dividenden | Nein |
Beta | 2,37 |
KGV (PE Ratio) | −0,12 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,21 |
KUV (PS Ratio) | 0,44 |
Unternehmensprofil
Name | Bionano Genomics |
CEO | Dr. Robert Erik Holmlin M.B.A., Ph.D. |
Sitz | San Diego, ca USA |
Website | |
Industrie | Biotechnologie |
Mitarbeiter | 98 |
Assets entdecken
Shareholder von Bionano Genomics investieren auch in folgende Assets